

[Back to Search Results](#)

Dissecting Bubonic Plague

 [Description](#) [Details](#) [Sub-Projects](#) [Publications](#) [Patents](#) [Outcomes](#) [Clinical Studies](#) [News and More](#) [History](#) [Similar Projects](#)Project Number
5R01AI119032-05Contact PI/Project Leader
MILLER, VIRGINIA LAwardee Organization
**UNIV OF NORTH
CAROLINA CHAPEL HILL** [Share](#)

Description

Abstract Text

DESCRIPTION (provided by applicant): Yersinia pestis is the causative agent of **disease** in a variety of mammals, and humans can become infected when human and animal ecologies intersect. This has led to several pandemics of plague in human history, and infection with Y. pestis is currently considered by the WHO as a **re-emerging infectious disease** because of the increased incidence in a wide number of countries. Bubonic plague (transmitted via flea bite) is the most common form of **disease** and the untreated mortality rate is estimated at 40-70%. Mice are a natural host for Y. pestis and have long been used to study interactions of Y. pestis with a mammal during its normal cycle. Advantages of this are that we can use fully virulent bacteria and small inocula; furthermore, Y. pestis is genetically tractable allowing detailed analyses. These features are useful for gaining a fuller understanding of Y. pestis-host interactions, and it also make Y. pestis a useful and very sensitive model for understanding the hurdles an arthropod borne pathogen needs to overcome. We recently refined an intradermal infection model (to better mimic inoculation via a flea) and also developed a dissemination assay that allows us to monitor population dynamics at very early time points. Our recent results indicate there is a strong bottleneck between the inoculation site and establishment of infection in the draining lymph node (dLN), that neutrophils are not needed either for trafficking to the dLN or for the bottleneck, and that the bacteria can disseminate as free bacteria in the lymphatics. These observations lead to the hypothesis that specific bacterial determinants are not required for trafficking to the dLN but are required for establishing infection in the dLN and/or dissemination from the dLN to systemic sites. Our long-term goal is to understand the early events ultimately leading to a successful systemic infection and transmission to a new host. Specifically we propose to determine how known virulence factors affect specific steps between the inoculation site and blood, and how key host cells affect the development of pathology and systemic colonization. Together these studies will give us a clearer picture of how host-pathogen interactions and specific virulence determinants affect development of bubonic plague, providing a foundation for development of intervention strategies.

Public Health Relevance Statement

PUBLIC HEALTH RELEVANCE: Yersinia pestis, a highly pathogenic bacterium, is the causative agent of disease in humans with bubonic plague being the most frequent form of the disease; it is considered to be both a bioterrorism threat and a re-emerging pathogen due to the increase in incidence in a wide number of countries. Here we propose to do a 'flea-to-flea' analysis of bubonic plague including an assessment of the role of selected virulence determinants and selected host cells. This type of analysis will provide valuable information regarding potential key check points during infection and thus potential targets for intervention.

NIH Spending Category

Biodefense Emerging Infectious Diseases Infectious Diseases Rare Diseases
Vector-Borne Diseases

Project Terms

Affect Appearance Arthropods Bacteria Biological Assay Bioterrorism
Bite Blood Bubonic Plague Cells Cessation of life Country Data

Thank you for your feedback!

[Back to Search Results](#)

Dissecting Bubonic Plague

[!\[\]\(0f848bbd71cef6b345273b16f905912a_img.jpg\) Description](#)Project Number
5R01AI119032-05Contact PI/Project Leader
MILLER, VIRGINIA LAwardee Organization
**UNIV OF NORTH
CAROLINA CHAPEL HILL**[!\[\]\(3211b5d1d968fc1665909b34f9f16010_img.jpg\) Details](#)[!\[\]\(6059a5aa8b4ca7bb793408023d6c6e42_img.jpg\) Sub-Projects](#)

Oligonucleotides

Pathogenesis

Pathology

Phagocytes

Phenotype

[!\[\]\(f1c5da15572e3e09d343161be98f508d_img.jpg\) Publications](#)

Read More

[!\[\]\(eabd9f9ababee93effadc3b380fe65fd_img.jpg\) Patents](#)[!\[\]\(83bbbd261710c59db0214aa27b2edc0d_img.jpg\) Outcomes](#)[!\[\]\(166772600a13ad0a433053f90fe45649_img.jpg\) Clinical Studies](#)[!\[\]\(291e070cef6c4d5e78fefe4696ef53be_img.jpg\) News and More](#)[!\[\]\(a73c1962d20a39dd8fd6a060ae69693f_img.jpg\) History](#)[!\[\]\(f507db636256ac11a5525ef93ec6b8d7_img.jpg\) Similar Projects](#)

Details

Contact PI/ Project**Leader****Other PIs****Program Official**

Not Applicable

Name

MUKHOPADHYAY, SUMAN

Contact

[**mukhopadhyays@mail.nih.gov**](mailto:mukhopadhyays@mail.nih.gov)

Name

[**MILLER, VIRGINIA L**](#)

Title

PROFESSOR

Contact

[**VIRGINIA@BORCIM.WUSTL.EDU**](mailto:VIRGINIA@BORCIM.WUSTL.EDU)**Organization**

Name

**UNIV OF NORTH CAROLINA
CHAPEL HILL**

Department Type

MICROBIOLOGY/IMMUN/VIROLOGY

State Code

NC

City

CHAPEL HILL

Organization Type

SCHOOLS OF MEDICINE

Congressional District

04

Country

UNITED STATES (US)**Other Information**

FOA

[**PA-13-302**](#)

Study Section

[**Bacterial Pathogenesis Study
Section\[BACP\]**](#)Administering Institutes or
Centers**NATIONAL INSTITUTE OF
ALLERGY AND INFECTIOUS
DISEASES**Project Start
Date**01-May-
2015**DUNS Number CFDA Code
608195277 855Project End
Date**30-April-
2020**

Fiscal Year

2019

Award Notice

Date

17-April-2019Budget Start
Date**01-May-
2019**Budget End
Date**30-April-
2020****Project Funding Information for 2019**Total Funding
\$376,547Direct Costs
\$250,000Indirect Costs
\$126,547

Year	Funding IC	
2019	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$376,547

NIH Categorical Spending[Click here for more information on NIH Categorical Spending](#)

Funding IC	FY Total Cost by IC	NIH Spending Category
------------	---------------------	-----------------------

Thank you for your feedback!

[Back to Search Results](#)

Dissecting Bubonic Plague

 [Description](#)Project Number
5R01AI119032-05Contact PI/Project Leader
MILLER, VIRGINIA LAwardee Organization
**UNIV OF NORTH
CAROLINA CHAPEL HILL** [Details](#) [Sub-Projects](#) [Publications](#) [Patents](#) [Outcomes](#) [Clinical Studies](#) [News and More](#) [History](#) [Similar Projects](#)

Sub Projects

No Sub Projects information available for 5R01AI119032-05

Publications

No Publications available for 5R01AI119032-05

Patents

No Patents information available for 5R01AI119032-05

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 5R01AI119032-05

Clinical Studies

No Clinical Studies information available for 5R01AI119032-05

News and More

Related News Releases

No news release information available for 5R01AI119032-05

History

No Historical information available for 5R01AI119032-05

Thank you for your feedback!

[Back to Search Results](#)

Dissecting Bubonic Plague

 [Description](#)Project Number
5R01AI119032-05Contact PI/Project Leader
MILLER, VIRGINIA LAwardee Organization
**UNIV OF NORTH
CAROLINA CHAPEL HILL** [Details](#) [Sub-Projects](#) [Publications](#) [Patents](#) [Outcomes](#) [Clinical Studies](#) [News and More](#) [History](#) [Similar Projects](#)

Thank you for your feedback!